Article

ORBIS president and board member, The Honorable Oliver Foot, dies

ORBIS International in a statement announced its sadness at the death of its president and member of the board of directors, the Honorable Oliver Foot.

New York-ORBIS International in a statement announced its sadness at the death of its president and member of the board of directors, the Honorable Oliver Foot. He was 61 years old.

Foot joined ORBIS as executive director in 1982 and was appointed president in 1987. He served as a ORBIS international board member, as well as a member of ORBIS Canada and ORBIS Taiwan.

He was dedicated to reduce human suffering caused by blindness and this was evident in his work with ORBIS. Foot led the ORBIS team of voluntary physicians, nurses, and aviators who flew to nearly 80 developing countries. Also, he led fundraising efforts that raised more than $200 million in North America, the United Kingdom, the Middle East, and Hong Kong to fund the humanitarian work of ORBIS

"Oliver's passing is of enormous import to ORBIS as an organization but also to a great many of us as individuals. He gave so much of himself and was such a kind and generous spirit that he was loved all over the world. He certainly meant a lot to me as a mentor, boss, friend, and brother, and I cannot imagine feeling any loss more deeply," said Geoffrey Holland, ORBIS executive director and chief executive officer. "I hope that while mourning the loss of such a very special friend, we can all also celebrate his life and remember what a pleasure it has been to know him."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.